Hepatitis C Treatment Entering a New Era- Pharmacy Technician

  Price  

  Credits  1.5

This product is currently out of stock and unavailable.


Format
Hepatitis C virus (HCV) infection is estimated to affect over 4 million Americans - almost 2-3% of the population. Most Americans with hepatitis C acquired it in the 1970s and 1980s, before the virus was identified. Although the rate of new infections has declined, HCV remains a major public health concern. Chronic HCV infection is the leading cause of cirrhosis, liver cancer, and end-stage liver disease requiring transplantation. Early detection and antiviral treatment to eradicate the virus can reduce the risk of progressive disease and death. The arrival of boceprevir (Victrelis™) and telaprevir (Incivek™), the first HCV protease inhibitors (PIs), marks the beginning of a new era of therapy for hepatitis C. PI-based therapy is complex, however; both PIs require co-treatment with ribavirin and peginterferon alfa-2a or alfa-2b. Treatment involves a high pill burden, significant side effects, and many potential drug interactions. This issue provides a detailed review of the new PI-based treatment regimens, including tips on managing side effects and avoiding drug interactions. The Patient Connection answers common questions about how hepatitis C is acquired, who is at risk, and how to prevent transmission.

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Tech Drug Therapy

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

Course Accreditation

  • Activity Type:
    Knowledge
  • CE Broker
  • Universal Activity Number:
    Pharmacy Technician : 0428-0000-12-002-H01-T
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.